Detalhe da pesquisa
1.
Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan.
Haematologica
; 103(11): 1835-1842, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-29976734
2.
A spindle cell variant of diffuse large B-cell lymphoma is characterized by T-cell/myofibrohistio-rich stromal alterations: analysis of 10 cases and a review of the literature.
Eur J Haematol
; 89(4): 302-10, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22738254
3.
Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response.
NPJ Syst Biol Appl
; 8(1): 39, 2022 10 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36229495
4.
[Therapeutic choice for the chronic myeloid leukemia patients in chronic phase showing late suboptimal response to imatinib].
Rinsho Ketsueki
; 51(12): 1762-8, 2010 Dec.
Artigo
em Japonês
| MEDLINE | ID: mdl-21258186
5.
Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic-phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5 ): The phase 2, multicenter N-Road study.
Cancer Med
; 9(11): 3742-3751, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32253827
6.
Characterization of interface of Al-Ni/a-Si for thin film transistor using high-resolution Rutherford backscattering spectrometry.
Micron
; 40(1): 66-9, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-18313311
7.
Potential utility of serum soluble LR11 as a diagnostic biomarker for intravascular large B-cell lymphoma.
Leuk Lymphoma
; 55(10): 2391-4, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24401112